280Bio initiates Phase 1 clinical study for YL-17231 after FDA approval
In a significant breakthrough for 280Bio, Inc., a clinical-stage biotechnology company, the US Food and Drug Administration (FDA) has given the green light to its ... Read More
RemeGen, Innovent Biologics to collaborate on clinical trials for combination therapies with ADCs
RemeGen, a commercial-stage Chinese biotechnology firm, and Innovent Biologics have announced their collaboration in a clinical research and supply agreement. This partnership focuses on conducting ... Read More
Thermo Fisher Scientific launches Gibco OncoPro Tumoroid Culture Medium Kit
Fisher Scientific, a global leader in serving science, unveiled its latest product, the Gibco OncoPro Tumoroid Culture Medium Kit to expedite development of novel cancer ... Read More
ALX Oncology gets EC’s orphan drug status for evorpacept in gastric cancer
ALX Oncology Holdings, an Australian immuno-oncology company focusing on CD47 checkpoint pathway blocking therapies, declared a significant milestone with its flagship drug candidate evorpacept securing ... Read More
Yashoda Hospital, Elekta introduce Unity MR Linac for cancer treatment
Yashoda Hospital, in partnership with Elekta, a Swedish developer of precision radiation therapy, has introduced the latter’s Unity MR Linac system in India, marking a ... Read More
MEDiC Life Sciences, Bristol Myers Squibb to advance discovery of tumor targets
MEDiC Life Sciences, a biotech startup based in Silicon Valley, has announced a research collaboration with pharmaceutical giant Bristol Myers Squibb to advance the discovery ... Read More
Invivoscribe, Complete Genomics to develop biomarker tests for oncology research
Invivoscribe and Complete Genomics have announced a partnership aimed at developing and commercializing biomarker tests on the latter’s next-generation sequencing (NGS) platforms. The collaboration, covering ... Read More
Sesen Bio gets shareholders’ approval for merger with Carisma Therapeutics
Nasdaq-listed Sesen Bio said that its stockholders have approved the previously announced merger deal with Carisma Therapeutics aimed at creating a clinical-stage biotechnology company for ... Read More
Moderna, Merck get FDA breakthrough status for mRNA-4157/V940, KEYTRUDA combo in melanoma
Moderna and Merck announced that the investigational personalized mRNA cancer vaccine mRNA-4157/V940 in combination with the latter’s lung cancer drug KEYTRUDA (pembrolizumab) has been given ... Read More
Gilead gets Trodelvy FDA approval for pre-treated HR+/HER2- metastatic breast cancer
Gilead Sciences has secured the approval of the US Food and Drug Administration (FDA) for Trodelvy (sacituzumab govitecan-hziy) for pre-treated HR+/HER2- metastatic breast cancer. The ... Read More